Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I.

Fehr M, Maranta AF, Reichegger H, Gillessen S, Cathomas R.

ESMO Open. 2018 Mar 8;3(3):e000320. doi: 10.1136/esmoopen-2018-000320. eCollection 2018.

2.

Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland.

Sandmeier N, Rothschild SI, Rothermundt C, Cathomas R, Schardt J, Berthold D, von Burg P, Müller B, Beyer J, Vogt DR, Stenner F.

Clin Genitourin Cancer. 2018 Feb 2. pii: S1558-7673(18)30029-6. doi: 10.1016/j.clgc.2018.01.002. [Epub ahead of print]

PMID:
29503245
3.

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program.

Balmelli C, Railic N, Siano M, Feuerlein K, Cathomas R, Cristina V, Güthner C, Zimmermann S, Weidner S, Pless M, Stenner F, Rothschild SI.

J Cancer. 2018 Jan 1;9(2):250-255. doi: 10.7150/jca.22318. eCollection 2018.

4.

Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.

Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, Wild D.

J Nucl Med. 2018 Jun;59(6):915-921. doi: 10.2967/jnumed.117.199760. Epub 2017 Nov 30.

PMID:
29191855
5.

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.

Heinrich D, Bektic J, Bergman AM, Caffo O, Cathomas R, Chi KN, Daugaard G, Keizman D, Kindblom J, Kramer G, Olmos D, Omlin A, Sridhar SS, Tucci M, van Oort I, Nilsson S.

Clin Genitourin Cancer. 2017 Sep 6. pii: S1558-7673(17)30275-6. doi: 10.1016/j.clgc.2017.08.020. [Epub ahead of print]

6.

Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry.

Stenner F, Rothschild SI, Betticher D, Caspar C, Morant R, Popescu R, Rauch D, Huber U, Zenhäusern R, Rentsch C, Cathomas R.

Clin Genitourin Cancer. 2017 Aug 24. pii: S1558-7673(17)30244-6. doi: 10.1016/j.clgc.2017.08.003. [Epub ahead of print]

PMID:
28958629
7.

Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database.

Keizman D, Fosboel MO, Reichegger H, Peer A, Rosenbaum E, Desax MC, Neiman V, Petersen PM, Mueller J, Cathomas R, Gottfried M, Dresler H, Sarid D, Mermershtain W, Rouvinov K, Mortensen J, Gillessen S, Daugaard G, Omlin A.

Prostate Cancer Prostatic Dis. 2017 Sep;20(3):289-293. doi: 10.1038/pcan.2017.6. Epub 2017 Feb 28.

PMID:
28244493
8.

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.

Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF; Swiss Group for Clinical Cancer Research.

Clin Lung Cancer. 2017 May;18(3):303-309. doi: 10.1016/j.cllc.2016.11.007. Epub 2016 Nov 23.

PMID:
27993482
9.

Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.

Mey UJ, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna CJ, Schmid M, Schmidt-Hieber M, Doerfel S, Fischer N, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Driessen C.

Br J Haematol. 2017 Mar;176(5):770-782. doi: 10.1111/bjh.14481. Epub 2016 Dec 16.

PMID:
27983764
10.

Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11).

Cathomas R, Crabb SJ, Mark M, Winterhalder R, Rothermundt C, Elliott T, von Burg P, Kenner H, Hayoz S, Vilei SB, Rauch D, Roggero E, Mohaupt MG, Bernhard J, Manetsch G, Gillessen S; Swiss Group for Clinical Cancer Research SAKK.

Prostate. 2016 Dec;76(16):1519-1527. doi: 10.1002/pros.23236. Epub 2016 Jul 25.

PMID:
27457964
11.

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.

Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na KJ, Bärtschi D, Borner M, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R; Swiss Group for Clinical Cancer Research (SAKK).

BMC Cancer. 2016 Oct 10;16(1):780.

12.

Multitargeted Kinase Inhibition in Metastatic Differentiated Radioiodine-Refractory Thyroid Cancer: A Look at New Therapeutic Options for a Rare Disease.

Mischler K, Kneifel S, Cathomas R.

Oncol Res Treat. 2016;39(9):548-52. doi: 10.1159/000448387. Epub 2016 Aug 10. Review.

13.

Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program.

Papazoglou D, Wannesson L, Berthold D, Cathomas R, Gillessen S, Rothermundt C, Hasler L, Winterhalder R, Barth A, Mingrone W, Nussbaum CU, von Rohr L, von Burg P, Schmid M, Richner J, Baumann S, Kühne R, Stenner F, Rothschild SI.

Clin Genitourin Cancer. 2017 Jun;15(3):e315-e323. doi: 10.1016/j.clgc.2016.06.011. Epub 2016 Jun 23.

PMID:
27450512
14.

Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases.

Metaxas Y, Cathomas R, Mark M, von Moos R.

Lung Cancer. 2016 Dec;102:136-138. doi: 10.1016/j.lungcan.2016.07.012. Epub 2016 Jul 14.

PMID:
27440191
15.

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators.

Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21.

16.

Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.

Seidel C, Oechsle K, Lorch A, Dieing A, Hentrich M, Hornig M, Grünwald V, Cathomas R, Meiler J, de Wit M, Bokemeyer C.

Urol Oncol. 2016 Apr;34(4):167.e21-8. doi: 10.1016/j.urolonc.2015.11.007. Epub 2015 Dec 11.

PMID:
26699830
17.

The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06).

Strasser F, Blum D, von Moos R, Cathomas R, Ribi K, Aebi S, Betticher D, Hayoz S, Klingbiel D, Brauchli P, Haefner M, Mauri S, Kaasa S, Koeberle D; Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2016 Feb;27(2):324-32. doi: 10.1093/annonc/mdv576. Epub 2015 Dec 8.

18.

Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic non-small cell lung cancer: a single center 10-year experience.

Volk V, Cathomas R, Mark M, von Moos R, Klingbiel D, Brossart P, Mey U.

Support Care Cancer. 2016 May;24(5):2119-2128. doi: 10.1007/s00520-015-3015-z. Epub 2015 Nov 9.

PMID:
26553033
19.

Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.

Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebersold DM, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik IF, Weder W.

Lancet Oncol. 2015 Dec;16(16):1651-8. doi: 10.1016/S1470-2045(15)00208-9. Epub 2015 Nov 2.

PMID:
26538423
20.

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.

Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, Gerard MA, Xyrafas A, Früh M, Cathomas R, Zippelius A, Roth A, Bijelovic M, Ochsenbein A, Meier UR, Mamot C, Rauch D, Gautschi O, Betticher DC, Mirimanoff RO, Peters S; SAKK Lung Cancer Project Group.

Lancet. 2015 Sep 12;386(9998):1049-56. doi: 10.1016/S0140-6736(15)60294-X. Epub 2015 Aug 11. Erratum in: Lancet. 2015 Sep 12;386(9998):1040.

PMID:
26275735
21.

Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience.

Chau C, Cathomas R, Wheater M, Klingbiel D, Fehr M, Bennett J, Markham H, Lee C, Crabb SJ, Geldart T.

Ann Oncol. 2015 Sep;26(9):1865-70. doi: 10.1093/annonc/mdv254. Epub 2015 Jun 2.

PMID:
26037797
22.

Improved survival of older patients with multiple myeloma in the era of novel agents.

Mey UJ, Leitner C, Driessen C, Cathomas R, Klingbiel D, Hitz F.

Hematol Oncol. 2016 Dec;34(4):217-223. doi: 10.1002/hon.2205. Epub 2015 Apr 21.

PMID:
25898820
23.

Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.

Gautschi O, Mach N, Rothschild SI, Li Q, Stahel RA, Zippelius A, Cathomas R, Früh M, Betticher DC, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut EO, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein AF; Swiss Group for Clinical Cancer Research.

Clin Lung Cancer. 2015 Sep;16(5):358-65. doi: 10.1016/j.cllc.2015.02.007. Epub 2015 Mar 5.

PMID:
25843489
24.

First-line treatment of metastatic disease: cisplatin-ineligible patients.

Cathomas R, De Santis M, Galsky MD.

Hematol Oncol Clin North Am. 2015 Apr;29(2):329-40, x. doi: 10.1016/j.hoc.2014.10.006. Epub 2014 Dec 15. Review.

PMID:
25836938
25.

Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).

Joerger M, van Schaik RH, Becker ML, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen S, Rothermundt C.

Prostate Cancer Prostatic Dis. 2015 Jun;18(2):167-72. doi: 10.1038/pcan.2015.8. Epub 2015 Mar 10.

PMID:
25753371
26.

Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel.

Omlin A, Sartor O, Rothermundt C, Cathomas R, De Bono JS, Shen L, Su Z, Gillessen S.

Clin Genitourin Cancer. 2015 Aug;13(4):e205-8. doi: 10.1016/j.clgc.2015.01.010. Epub 2015 Jan 30.

PMID:
25733056
27.

RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward?

Cathomas R, Rothermundt C, Bode B, Fuchs B, von Moos R, Schwitter M.

Oncology. 2015;88(4):257-60. doi: 10.1159/000369975. Epub 2014 Dec 17.

28.

Bilocal recurrence of a neuroendocrine carcinoma of the small intestine: A case report.

Peiffer S, Cathomas R, Villiger P.

Int J Surg Case Rep. 2014;5(12):1117-9. doi: 10.1016/j.ijscr.2014.11.004. Epub 2014 Nov 10.

29.

Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.

Brunner S, von Moos R, Mey U, Camenisch Gross U, Freyholdt T, Cathomas R.

Oncol Res Treat. 2014;37(11):646-52. doi: 10.1159/000368313. Epub 2014 Oct 17.

PMID:
25427581
30.

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.

Sebastian M, Papachristofilou A, Weiss C, Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen KJ, Gnad-Vogt U, Zippelius A.

BMC Cancer. 2014 Oct 6;14:748. doi: 10.1186/1471-2407-14-748.

31.

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.

Del Conte G, Sessa C, von Moos R, Viganò L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A, Cathomas R, Gianni L.

Br J Cancer. 2014 Aug 12;111(4):651-9. doi: 10.1038/bjc.2014.345. Epub 2014 Jul 15.

32.

Measurement or estimation of glomerular filtration rate in seminoma patients: quite another cup of tea.

Fehr M, Geldart T, Klingbiel D, Cathomas R.

Eur J Cancer. 2014 Aug;50(12):2176-7. doi: 10.1016/j.ejca.2014.04.028. Epub 2014 Jun 7. No abstract available.

PMID:
24915777
33.

Management of bone metastases in patients with castration-resistant prostate cancer.

Cathomas R, Bajory Z, Bouzid M, El Ghoneimy A, Gillessen S, Goncalves F, Kacso G, Kramer G, Milecki P, Pacik D, Tantawy W, Lesniewski-Kmak K.

Urol Int. 2014;92(4):377-86. doi: 10.1159/000358258. Epub 2014 Apr 30. Review.

34.

Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort.

Cathomas R, Klingbiel D, Geldart TR, Mead GM, Ellis S, Wheater M, Simmonds P, Nagaraj N, von Moos R, Fehr M.

Ann Oncol. 2014 Aug;25(8):1591-7. doi: 10.1093/annonc/mdu129. Epub 2014 Mar 25.

PMID:
24669017
35.

Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).

Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bärtschi D, Pollak M, Lui L, Endt K, Schiess R, Rüschoff JH, Cathomas R, Gillessen S.

Eur Urol. 2014 Sep;66(3):468-74. doi: 10.1016/j.eururo.2013.12.057. Epub 2014 Jan 4.

PMID:
24412228
36.

Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial.

Stenner-Liewen F, Liewen H, Cathomas R, Renner C, Petrausch U, Sulser T, Spanaus K, Seifert HH, Strebel RT, Knuth A, Samaras P, Müntener M.

J Cancer. 2013 Aug 29;4(7):597-605. doi: 10.7150/jca.7123. eCollection 2013.

37.

EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.

Baty F, Rothschild S, Früh M, Betticher D, Dröge C, Cathomas R, Rauch D, Gautschi O, Bubendorf L, Crowe S, Zappa F, Pless M, Brutsche M; Swiss Group for Clinical Cancer Research.

PLoS One. 2013 Sep 10;8(9):e72966. doi: 10.1371/journal.pone.0072966. eCollection 2013.

38.

Active surveillance is the preferred approach to clinical stage I testicular cancer.

Nichols CR, Roth B, Albers P, Einhorn LH, Foster R, Daneshmand S, Jewett M, Warde P, Sweeney CJ, Beard C, Powles T, Tyldesley S, So A, Porter C, Olgac S, Fizazi K, Hayes-Lattin B, Grimison P, Toner G, Cathomas R, Bokemeyer C, Kollmannsberger C.

J Clin Oncol. 2013 Oct 1;31(28):3490-3. doi: 10.1200/JCO.2012.47.6010. Epub 2013 Sep 3. No abstract available.

PMID:
24002502
39.

The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patients.

Clough-Gorr KM, Noti L, Brauchli P, Cathomas R, Fried MR, Roberts G, Stuck AE, Hitz F, Mey U.

BMC Med Inform Decis Mak. 2013 Aug 23;13:93. doi: 10.1186/1472-6947-13-93.

40.

[Integration of drug treatment in the management concept of prostate cancer].

Cathomas R.

Internist (Berl). 2013 Oct;54(10):1262-70. doi: 10.1007/s00108-013-3334-4. Review. German.

PMID:
23896735
41.

Optimizing treatment of seminoma stage IIA/B step by step.

Papachristofilou A, Cathomas R, Bedke J, Souchon R, Kolb C, Gillessen S.

Ann Oncol. 2013 Sep;24(9):2463. doi: 10.1093/annonc/mdt272. Epub 2013 Jul 17. No abstract available.

PMID:
23864099
42.

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).

Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Müller B, Schiess R, Wild PJ, Rüschoff JH, Thalmann G, Dietrich PY, Aebersold R, Klingbiel D, Gillessen S; Swiss Group for Clinical Cancer Research (SAKK).

Eur Urol. 2013 Jul;64(1):150-8. doi: 10.1016/j.eururo.2013.03.040. Epub 2013 Apr 6.

PMID:
23582881
43.

Multidisciplinary care in patients with prostate cancer: room for improvement.

Strebel RT, Sulser T, Schmid HP, Gillessen S, Fehr M, Huber U, Pless M, Morant R, Winterhalder R, Cathomas R.

Support Care Cancer. 2013 Aug;21(8):2327-33. doi: 10.1007/s00520-013-1791-x. Epub 2013 Mar 26.

PMID:
23529667
44.

A phase I study of the oral platinum agent satraplatin in combination with oral vinorelbine in patients with advanced solid malignancies.

Gallerani E, Cathomas R, Sessa C, Digena T, Bartosek AA, Dal Zotto L, von Moos R.

Onkologie. 2013;36(1-2):40-5. doi: 10.1159/000346671. Epub 2013 Jan 28.

PMID:
23429330
45.

Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer.

Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Claßen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germá Lluch JR, Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LH, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C.

Ann Oncol. 2013 Apr;24(4):878-88. doi: 10.1093/annonc/mds579. Epub 2012 Nov 14.

46.

[Treatment of metastatic melanoma: are we entering the era of targeted treatment?].

von Moos R, Cathomas R, Mark M, Hitz F.

Praxis (Bern 1994). 2012 Oct 31;101(22):1423-9. doi: 10.1024/1661-8157/a001030. Review. German.

PMID:
23117962
47.

[Advances in the treatment of prostate cancer - dawn of a new era].

Merki R, Cathomas R.

Ther Umsch. 2012 Oct;69(10):585-90. doi: 10.1024/0040-5930/a000334. German.

PMID:
23026884
48.

Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).

Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold DR, Pless M, Schiess R, von Moos R, Gillessen S; Swiss Group for Clinical Cancer Research SAKK.

Clin Cancer Res. 2012 Nov 1;18(21):6049-57. doi: 10.1158/1078-0432.CCR-12-2219. Epub 2012 Sep 12.

49.

A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.

Stenner F, Chastonay R, Liewen H, Haile SR, Cathomas R, Rothermundt C, Siciliano RD, Stoll S, Knuth A, Buchler T, Porta C, Renner C, Samaras P.

Oncology. 2012;82(6):333-40. doi: 10.1159/000338001. Epub 2012 Jun 2.

50.

Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).

Früh M, Cathomas R, Siano M, Tscherry G, Zippelius A, Mamot C, Erdmann A, Krasniqi F, Rauch D, Simcock M, Küttel E, Fustier P, Pless M; Swiss Group for Clinical Cancer Research.

Clin Lung Cancer. 2013 Jan;14(1):34-9. doi: 10.1016/j.cllc.2012.04.001. Epub 2012 May 24.

PMID:
22633220

Supplemental Content

Loading ...
Support Center